Medical cannabis in Switzerland: Why access for patients remains difficult
Since 2022, doctors in Switzerland have been allowed to prescribe medical cannabis without special authorization from the Federal Office of Public Health. This legislative change was intended to significantly facilitate access for patients with chronic pain or serious illnesses. However, two years after its introduction, it is clear that the reality for those affected is more complicated than expected.
A central problem is finding a suitable medical practice. Many physicians remain hesitant to prescribe cannabis products. This is often due to a lack of training on the subject or concerns about bureaucratic effort. Consequently, patients frequently report that they have to search for a long time to find a doctor willing to oversee such a therapy.
Additionally, the question of costs poses a major hurdle. Although cannabis can be prescribed medically, health insurance companies generally do not cover the costs automatically. Patients often have to pay large amounts out of their own pockets, as the effectiveness for many medical conditions is not yet considered sufficiently proven by insurers. This often excludes low-income patients from treatment.
The medical community is currently discussing the future of cannabis therapy intensively. Experts are calling for better education for doctors as well as clearer guidelines for cost coverage by basic insurance. Only in this way can it be ensured that the 2022 legislative change achieves its actual goal: unbureaucratic and fair medical care for all people in need in Switzerland.